drugset / Trial / NCT03639935
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Phase 2
Completed
32 enrolled
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute · collabVanderbilt University Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.
Timeline
- Start
- 2019-03-28
- Primary completion
- 2023-02-07
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Rucaparib | Small molecule | 600 mg | Oral |